English Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil

Archivos en Investigación del Cáncer

  • ISSN: 2254-6081
  • Índice h de la revista: 13
  • Puntuación de cita de revista: 3.58
  • Factor de impacto de la revista: 3.12
Indexado en
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • CiteFactor
  • OCLC-WorldCat
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • Google Académico
  • Laboratorios secretos de motores de búsqueda
Ver más
Comparte esta página

Abstracto

Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review on Toxicity Profiles

Aileen Deng, Andrew Chapman and Jianqing Lin

Tyrosine kinase inhibitors (TKIs) have emerged as the mainstay treatment for renal cell carcinoma (RCC). Despite growing popularity of TKIs, the treatment safety and tolerability in elderly patients are yet to be fully understood. As new assessment tools become available in identifying elderly patients with cancer at risk for severe treatment-related toxicities, much remains to be learned about how to integrate these tools into our management of elderly patients with cancer. We present a case of a 75- year-old man with RCC who was initially treated with pazopanib and subsequently treated with sunitinib. We review the safety and toxicity profiles of TKIs in treating elderly patients with RCC.

Descargo de responsabilidad: este resumen se tradujo utilizando herramientas de inteligencia artificial y aún no ha sido revisado ni verificado